Scarica l'app Stockscreener
1.26
5.88%
0.07
Pre-mercato:
1.22
-0.04
-3.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.19
Aprire:
$1.22
Volume 24 ore:
782.56K
Relative Volume:
1.27
Capitalizzazione di mercato:
$56.18M
Reddito:
-
Utile/perdita netta:
$-40.56M
Rapporto P/E:
-1.0769
EPS:
-1.17
Flusso di cassa netto:
$-35.28M
1 W Prestazione:
-5.97%
1M Prestazione:
-16.00%
6M Prestazione:
-58.00%
1 anno Prestazione:
-73.47%
Intervallo 1D:
$1.19
$1.305
Intervallo di 1 settimana:
$1.16
$1.49
Portata 52W:
$1.16
$5.00
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Nome
Pds Biotechnology Corporation
Settore
Industria
Telefono
800-208-3343
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Confronta PDSB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.26 | 56.18M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-01 | Iniziato | B. Riley Securities | Buy |
| 2021-06-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-09 | Iniziato | Noble Capital Markets | Outperform |
| 2019-10-24 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com India
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times
PDS Biotech Leadership to Participate in March Conferences - The Manila Times
PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo
H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India
HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World
PDS Biotech begins phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech begins phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - The Manila Times
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors - The Globe and Mail
Understanding the Risks of Investing in PDS Biotechnology Corporation (PDSB) - Knox Daily
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock - Investing.com India
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock - Investing.com India
PDS Biotechnology Directors Increase Holdings with Recent Purchases - TradingView
PDSB stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
PDSB stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com India
EMV Capital portfolio company PDS Biotechnology raises $11mln - Proactive Investors Australia
PDS Biotechnology Launches Registered Direct Offering; Shares Up -February 27, 2025 at 12:02 pm EST - Marketscreener.com
PDS Biotechnology Corp. to Host Earnings Call - ACCESS Newswire
PDS Biotech secures $11 million in direct offering By Investing.com - Investing.com South Africa
PDS Biotech secures $11 million in direct offering - Investing.com India
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology - The Manila Times
Where Do Analysts Think The PDS Biotechnology Corporation (NASDAQ: PDSB) Is Going - Stocks Register
PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright - Defense World
PDS Biotech stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Nigeria
Do you want to know where to find good stock? Take a look at PDS Biotechnology Corporation’s (NASDAQ:PDSB) Sentiment Analysis – US Post News - US Post News
PDS Biotech stock plunges to 52-week low of $1.25 - Investing.com
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - The Manila Times
PDS Biotechnology Reports Promising Phase 2 Results for Versamune® HPV in Treating HPV16-Positive Cancers; Phase 3 Trial Planned for Q1 2025 - Nasdaq
Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial - StockTitan
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 - The Manila Times
Can PDS Biotech's Latest Oncology Developments Transform Cancer Treatment? CEO to Reveal Strategy - StockTitan
PDSB stock touches 52-week low at $1.3 amid market challenges - MSN
Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire
Cancer Vaccines Market on Track for Major Expansion in - One News Page
PDSB stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8%What's Next? - MarketBeat
Pds Biotechnology Corporation Azioni (PDSB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pds Biotechnology Corporation Azioni (PDSB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):